Duro-Tuss AX Chesty Cough Liquid Special Precautions

Very rare cases of chronically associated severe skin impairments such as Stevens Johnson Syndrome, Toxic Epidermal Necrolysis (TEN), Erythema Multiforme (EM) and Acute Generalized Exanthematous Pustulosis (AGEP) have been reported. In most cases, these could be explained by the severity of the underlying disease or concomitant administration of another drug. In the early stages of such severe skin reactions, initially only nonspecific flu-like symptoms appear, e.g. fever, arthralgia, runny nose, cough, and sore throat. If symptoms or signs of a progressive skin rash (sometimes associated with blisters or mucosal lesions) are present, ambroxol hydrochloride treatment should be discontinued immediately and medical advice should be sought.
In patients with impaired bronchial motility and copious secretions (as seen, for instance, in the rare and malignant primary ciliary dyskinesia), DURO-TUSS AX CHESTY COUGH Liquid must be used with caution because of the risk that secretions may accumulate.
In patients with impaired kidney function or severe liver disease, DURO-TUSS AX CHESTY COUGH Liquid should not be used except on medical advice. With ambroxol, as with any medicine that is metabolized hepatically and excreted renally, accumulation of the metabolites of ambroxol which are formed in the liver can be expected to occur in patients with severe renal failure.
Effects on Ability to Drive and Use Machine: There is no evidence from postmarketing data for an effect on the ability to drive and use machines. Studies on the effects on the ability to drive and use machines have not been performed.